GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BriaCell Therapeutics
BriaCell, an oncology biotech focused on breast cancer, shares reflect the potential of its immunotherapy platform. The price trajectory is highly speculative and depends on clinical trial results.
Share prices of companies in the market segment - Cancer women
BriaCell Therapeutics is an oncology company developing personalized immunotherapy for breast cancer. We've categorized it as a "Women's Cancer" company. The chart below shows how investors view this high-risk but potentially disruptive biotech segment.
Broad Market Index - GURU.Markets
BriaCell Therapeutics is a Canadian oncology company developing immunotherapy for breast cancer. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how BriaCell shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
BCTX - Daily change in the company's share price BriaCell Therapeutics
For BriaCell Therapeutics Corp., an immuno-oncology company, the daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data from its breast cancer treatments.
Daily change in the price of a set of shares in a market segment - Cancer women
BriaCell Therapeutics Corp. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with BCTX, a breast cancer-focused stock, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
BriaCell Therapeutics is a biotech company focused on women's health, particularly cancer treatment. Its shares are highly volatile and dependent on clinical trial results. These scientifically based movements are part of the complex picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BriaCell Therapeutics
For BriaCell Therapeutics Corp., the year-over-year trend is a story about the development of its personalized breast cancer vaccine. Its 12-month market cap is entirely dependent on clinical trial data. Positive results could offer new hope for patients with metastatic disease.
Annual dynamics of market capitalization of the market segment - Cancer women
As an early-stage biotech, BriaCell is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its cancer immunotherapy. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BriaCell Therapeutics is a focused bet on beating breast cancer. Its stock price is completely uncorrelated with the market, but is a direct response to clinical trial data. Its earnings chart is a heartbeat of patient and investor hopes, where any news event can trigger a sharp rise or fall.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BriaCell Therapeutics
BriaCell is an immuno-oncology company developing breast cancer vaccines. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its lead program is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Cancer women
BriaCell Therapeutics is developing personalized immunotherapy drugs for the treatment of breast cancer. Their approach involves creating a vaccine from tumor cells. The graph below illustrates the overall dynamics in the women's health and oncology sectors, where personalized medicine offers new hope.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies working at the cutting edge of science, such as immunotherapy, often move independently of the market. The chart below shows the overall sentiment. Does BriaCell Therapeutics live in a world of its own, where development news trumps overall market trends?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BriaCell Therapeutics
BriaCell, which develops personalized immunotherapies for breast cancer, is extremely sensitive to scientific news. Its weekly stock price is a direct response to the publication of clinical trial data that could confirm the potential of its innovative approach to treating this disease.
Weekly dynamics of market capitalization of the market segment - Cancer women
BriaCell operates in the highly competitive oncology sector, where investor sentiment drives global trends. Any significant success or failure in the industry impacts everyone's risk appetite. The chart will show whether BCTX is following the general flow of biotech speculation or whether its focus on breast cancer is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BriaCell Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how BCTX shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
BCTX - Market capitalization of the company BriaCell Therapeutics
BriaCell Therapeutics' stock price is a focused bet on breast cancer immunotherapy. Its market cap reflects investor hopes for its personalized vaccine. Its volatile dynamics are a classic biotech story, where any clinical trial result can lead to a sharp rise or fall.
BCTX - Share of the company's market capitalization BriaCell Therapeutics within the market segment - Cancer women
BriaCell Therapeutics is developing personalized immunotherapy for breast cancer. Its market share in the oncology sector is based on this innovative approach. The chart shows the market value of its platform, which uses whole cancer cells to stimulate an immune response.
Market capitalization of the market segment - Cancer women
BriaCell Therapeutics is developing immunotherapy for the treatment of breast cancer. The chart below shows the market capitalization of the oncology sector. This is the valuation of one of many innovative approaches aimed at "training" the immune system to attack tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
BriaCell is an oncology company developing personalized immunotherapy for breast cancer. Its market capitalization is based on the hope of developing an effective vaccine. The chart below shows the economic weight of companies working in this important field.
Book value capitalization of the company, segment and market as a whole
BCTX - Book value capitalization of the company BriaCell Therapeutics
BriaCell Therapeutics is based on cancer immunotherapy. The company's book value reflects its patents for its personalized breast cancer vaccine platform and cash flow for clinical trials. The chart below shows how the company is building a financial foundation for its innovative approach to cancer treatment.
BCTX - Share of the company's book capitalization BriaCell Therapeutics within the market segment - Cancer women
BriaCell Therapeutics, an oncology company, is focused on R&D. Its laboratories are its main tangible asset. The S_BCap_Seg chart shows its small share of physical infrastructure, which is typical for a biotech company.
Market segment balance sheet capitalization - Cancer women
BriaCell Therapeutics is developing immunotherapy for breast cancer. Its main asset is its scientific platform and patents, not its manufacturing facilities. The chart shows that its value is based on intangible assets and the potential of future drugs, which is typical of advanced biotechnology.
Book value of all companies included in the broad market index - GURU.Markets
BriaCell's assets are focused on personalized immunotherapy for breast cancer. The company's book value reflects its cell lines, laboratories, and capital for clinical trials. This is the material basis for creating a vaccine that trains the patient's immune system to attack tumor cells.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BriaCell Therapeutics
BriaCell Therapeutics is developing an immunotherapy for breast cancer. Its book value represents R&D funding. Its market capitalization represents the volatile valuation of its lead drug candidate, which fluctuates sharply based on clinical trial news and efficacy data.
Market to book capitalization ratio in a market segment - Cancer women
BriaCell Therapeutics is developing immunotherapy for breast cancer. It is a highly specialized biotech company. The chart shows how the market values its scientific approach and potential to help patients compared to its current assets.
Market to book capitalization ratio for the market as a whole
BriaCell Therapeutics is developing immunotherapy for breast cancer. The company's value is based on the potential of its scientific platform. The chart shows how the market valuation reflects investor confidence in scientific breakthroughs, creating a huge gap with book value, as is the case with many biotechs.
Debts of the company, segment and market as a whole
BCTX - Company debts BriaCell Therapeutics
BriaCell Therapeutics, an oncology company focused on breast cancer, is using debt to fund its clinical trials. This chart shows the capital raised to test its innovative immunotherapy, which is being developed as a personalized vaccine for late-stage patients.
Market segment debts - Cancer women
BriaCell Therapeutics is a clinical-stage oncology company developing personalized immunotherapy for breast cancer. Its future depends entirely on the results of clinical trials. This chart shows its financial position and the "headroom" for continued development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BriaCell Therapeutics
BriaCell Therapeutics is a biotech company specializing in breast cancer immunotherapy. This chart shows its reliance on debt. For a company operating in such a narrow and important field, debt is a risky fuel for costly clinical trials in the hopes of a breakthrough.
Market segment debt to market segment book capitalization - Cancer women
BriaCell Therapeutics is a biotech company specializing in breast cancer immunotherapy. This biotech chart shows how much capital is being raised to fund breakthrough but risky research. It helps understand how the company's financial position is typical for this research-intensive field.
Debt to book value of all companies in the market
BriaCell Therapeutics is developing personalized immunotherapy for breast cancer. This chart, showing the market's debt-to-book value ratio, is important for assessing the biotech investment climate. The market's willingness to fund breakthrough yet highly specialized approaches in oncology determines BriaCell's ability to move forward.
P/E of the company, segment and market as a whole
P/E - BriaCell Therapeutics
BriaCell Therapeutics is developing personalized immunotherapy for breast cancer. This chart reflects hopes for a breakthrough in this field. The high value of this indicator indicates expectations that its approach, which stimulates the patient's own immune system to fight the tumor, will be effective in difficult-to-treat cases.
P/E of the market segment - Cancer women
BriaCell Therapeutics Corp. is a biotech company. This chart shows the average price-to-earnings ratio for the biotech sector. A company's price-to-earnings ratio (P/E) is higher than average, indicating that investors view its personalized breast cancer immunotherapy as particularly promising.
P/E of the market as a whole
BriaCell Therapeutics is developing personalized immunotherapy for breast cancer. Its approach involves creating a vaccine from the patient's own cancer cells. This chart illustrates the risk appetite in biotech. The company's valuation depends entirely on the success of this innovative but complex technology in clinical trials and on investor confidence in the future of personalized oncology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BriaCell Therapeutics
BriaCell Therapeutics is an immuno-oncology company developing a personalized vaccine for the treatment of breast cancer. The graph reflects speculative revenue expectations, which are entirely dependent on the success of clinical trials and the potential of this innovative therapy.
%20P%2FE%20BriaCell%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BriaCell-Therapeutics&v=1772617922222 "Chart of the company's future (projected) P/E BriaCell Therapeutics")
Future (projected) P/E of the market segment - Cancer women
BriaCell Therapeutics is developing personalized immunotherapy for breast cancer. This chart shows its expected future profitability, allowing us to assess how highly the market values its innovative approach to creating a "cancer vaccine" for every patient.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-women&v=1772617922232 "Future (projected) P/E graph of the market segment - Cancer women")
Future (projected) P/E of the market as a whole
BriaCell Therapeutics is a biotech company developing immunotherapy for breast cancer. This is a highly specialized and risky field. The company's valuation is entirely dependent on clinical trial results and is not tied to the overall market forecasts shown in this chart.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772617922243 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage immuno-oncology company developing personalized vaccines for the treatment of breast cancer. Its financial performance reflects significant investment in clinical trials. This chart illustrates the financial costs of developing an innovative treatment approach that activates a patient's own immune system.
Profit of companies in the market segment - Cancer women
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing personalized therapies for breast cancer. This chart shows the profitability of its segment. Its unique approach could offer hope to patients with advanced disease. R&D costs impact current overall profitability, but success could be a breakthrough.
Overall market profit
BriaCell Therapeutics is a clinical-stage immuno-oncology company developing personalized vaccines against breast cancer. Its value and future depend solely on the success of clinical trials. This chart illustrates general economic cycles that do not affect BriaCell's scientific progress or potential to fight cancer.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BriaCell Therapeutics
BriaCell Therapeutics is developing personalized immunotherapy for breast cancer. This chart reflects analysts' future earnings expectations, based on the potential of its innovative approach. It demonstrates market confidence in the company's ability to successfully complete clinical trials and offer a new treatment option for patients.
%20profit%20of%20the%20company%20BriaCell%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BriaCell-Therapeutics&v=1772617922290 "Graph of future (projected) profit of the company BriaCell Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer women
BriaCell Therapeutics Corp. is an immuno-oncology company developing targeted therapies for breast cancer. This chart shows profitability projections for the women's cancer sector. It reflects expectations for personalized treatment approaches that could improve patient outcomes.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-women&v=1772617922339 "Graph of future (predicted) profits of companies in a market segment - Cancer women")
Future (predicted) profit of the market as a whole
BriaCell Therapeutics is developing an immunotherapy for breast cancer. For a biotech company, the market's profit forecast is an indicator of investment appetite. The expected growth, visible in the chart, suggests that investors will be more willing to fund risky but potentially life-saving clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772617922344 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BriaCell Therapeutics
BriaCell Therapeutics is a biotech company developing immunotherapy for breast cancer. Currently in the clinical stage, it has no revenue. Its P/S will become key after commercialization, reflecting investors' confidence in its personalized approach to cancer treatment.
P/S market segment - Cancer women
BriaCell Therapeutics is an immuno-oncology company developing personalized vaccines for the treatment of breast cancer. Their approach is aimed at stimulating the patient's own immune system to fight the tumor. The chart shows the market's confidence in their cutting-edge scientific approach and potential for personalized oncology.
P/S of the market as a whole
BriaCell Therapeutics is developing personalized immunotherapy for the treatment of breast cancer. The company has no commercial revenue, and its valuation reflects the hope of a breakthrough in the treatment of this disease. This chart, based on actual revenue, clearly demonstrates that BriaCell is betting on the future of personalized oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BriaCell Therapeutics
BriaCell Therapeutics is developing personalized immunotherapy for the treatment of breast cancer. This is a cutting-edge approach to oncology. This chart reflects investor expectations for future revenue from this innovative therapy, betting on the success of its clinical programs and the future of personalized medicine.
%20P%2FS%20BriaCell%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BriaCell-Therapeutics&v=1772617922425 "The graph of the company's future (projected) P/S BriaCell Therapeutics")
Future (projected) P/S of the market segment - Cancer women
BriaCell Therapeutics Corp. is an immuno-oncology company developing targeted and safe treatments for breast cancer. This chart shows how the market perceives the future commercial potential of its personalized vaccine. It compares it to other companies specializing in women's cancer, reflecting the expectations for its innovative approach.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20women&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-women&v=1772617922430 "Future (projected) P/S market segment graph - Cancer women")
Future (projected) P/S of the market as a whole
BriaCell Therapeutics is a biotech company developing immunotherapy for breast cancer. Its approach is based on the creation of personalized vaccines. This chart shows investor revenue projections, and BCTX exemplifies how personalized medicine and immuno-oncology are the main hopes in the fight against cancer.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772617922445 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company focused on developing targeted therapies for breast cancer. Because its drugs are in development, the company has no sales revenue. Any revenue shown in this chart likely comes from grants or partnerships.
Sales of companies in the market segment - Cancer women
BriaCell Therapeutics is a biotech company developing immunotherapy for breast cancer. It currently has no product revenue. The graph may reflect revenue from partnerships or grants, which are a key source of funding for its clinical trials.
Overall market sales
BriaCell Therapeutics is a biotech company developing immunotherapy for the treatment of breast cancer. Its success depends entirely on the results of clinical trials. This market overview chart has no bearing on BriaCell, whose mission is to offer new hope to patients with advanced cancer.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BriaCell Therapeutics
BriaCell Therapeutics is a biopharmaceutical company developing immunotherapy for breast cancer. Its revenue forecast depends on the success of clinical trials and the future commercial potential of its vaccine. This chart shows analysts' speculative expectations for its targeted approach.
%20sales%20of%20the%20company%20BriaCell%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BriaCell-Therapeutics&v=1772617922498 "Schedule of future (projected) sales of the company BriaCell Therapeutics")
Future (projected) sales of companies in the market segment - Cancer women
BriaCell Therapeutics is an immuno-oncology company developing personalized vaccines for the treatment of breast cancer. This chart displays projected revenue for the entire women's oncology segment. It provides insight into the growth of the market for advanced immunotherapy treatments, which is critical to BriaCell's future commercial success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-women&v=1772617922516 "Schedule of future (projected) sales of companies in the market segment - Cancer women")
Future (projected) sales of the market as a whole
BriaCell Therapeutics is a biotech company developing immunotherapy for breast cancer. Its future depends entirely on the success of clinical trials. This graph of overall market expectations reflects the investment climate. A positive environment facilitates raising the capital needed to fund expensive R&D projects in oncology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772617922547 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BriaCell Therapeutics
BriaCell Therapeutics is a biopharmaceutical company developing immunotherapy for breast cancer. This chart reflects the company's current status in clinical trials. It doesn't show revenue, but rather the amount of investment in developing an innovative cancer vaccine.
Market segment marginality - Cancer women
BriaCell Therapeutics is an immuno-oncology company developing personalized vaccines for the treatment of breast cancer. This chart illustrates the average profitability in the oncology sector. It provides an idea of the commercial potential of BriaCell's unique approach to treating this common disease, should its therapy prove effective.
Market marginality as a whole
BriaCell Therapeutics Corp. is an immunotherapy company focused on breast cancer treatment. This total revenue chart shows the success of its existing businesses, while BriaCell operates at the cutting edge of science, where potential breakthroughs could save countless lives and create enormous shareholder value.
Employees in the company, segment and market as a whole
Number of employees in the company BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage immuno-oncology company developing a therapy for breast cancer. Its small but focused team of scientists and clinicians is advancing an innovative treatment approach. This chart shows the size of the R&D team working on the personalized vaccine.
Share of the company's employees BriaCell Therapeutics within the market segment - Cancer women
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing targeted immunotherapies for the treatment of breast cancer. This chart highlights its focus on women's health. It reflects the percentage of leading oncologists and immunologists working on the development of an innovative "cancer vaccine" that BriaCell brings together under its umbrella.
Number of employees in the market segment - Cancer women
BriaCell Therapeutics Corp. is developing personalized immunotherapy for breast cancer. This chart shows employment in the women's cancer treatment sector. The growing number of scientists in this field reflects the tremendous efforts to develop more effective and less toxic treatments for this common cancer.
Number of employees in the market as a whole
BriaCell Therapeutics Corp. is an immuno-oncology company developing personalized vaccines for the treatment of breast cancer. Personalized medicine is the future of oncology. This graph shows overall employment, and these companies are at the forefront of science, offering hope to patients and creating jobs for scientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BriaCell Therapeutics (BCTX)
BriaCell Therapeutics is an oncology company focused on breast cancer. Its value reflects the hope of developing an effective therapy. This chart illustrates the enormous value the market places on each scientist working on this socially significant problem. It's a measure of potential and intellectual capital.
%20of%20the%20company%20BriaCell%20Therapeutics%20(BCTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BriaCell-Therapeutics-BCTX&v=1772617922672 "Chart of market capitalization per employee (in thousands of dollars) of the company BriaCell Therapeutics (BCTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer women
BriaCell Therapeutics is developing immunotherapy for breast cancer. In this highly specialized field of biotechnology, the company's market capitalization per employee reflects investors' hopes for a breakthrough. A high market capitalization suggests a large potential market if its personalized approach is successful.
%20by%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-women&v=1772617922698 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer women")
Market capitalization per employee (in thousands of dollars) for the overall market
BriaCell Therapeutics is an immuno-oncology company developing personalized therapy for breast cancer. This is a cutting-edge treatment approach. This chart reflects investors' hopes that the team of scientists will be able to prove the effectiveness of their unique approach and help patients.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772617922716 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BriaCell Therapeutics (BCTX)
BriaCell is a clinical-stage biotech company developing immunotherapy for breast cancer. It's an R&D business. This chart, in negative territory, shows how much investor capital is being burned for every scientist and doctor working on this personalized vaccine.
%20Chart%20BriaCell%20Therapeutics%20(BCTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BriaCell-Therapeutics-BCTX&v=1772617922744 "Company Profit Per Employee (in thousands of dollars) Chart BriaCell Therapeutics (BCTX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer women
BriaCell Therapeutics is an immuno-oncology company developing personalized vaccines for the treatment of breast cancer. This chart highlights the potential of their innovative approach. It illustrates the enormous value a successful therapy targeting one of the most common cancers could generate, a key consideration for biotech investors.
%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-women&v=1772617922751 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer women")
Profit per employee (in thousands of dollars) for the market as a whole
BriaCell Therapeutics is a biopharmaceutical company specializing in breast cancer immunotherapy. This highly specialized R&D center is located in the center of the company. This chart shows the investment intensity (expenses) per scientist working on this personalized vaccine. The goal is a high return upon approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772617922754 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BriaCell Therapeutics (BCTX)
BriaCell Therapeutics is a clinical-stage oncology company. This chart does not reflect current commercial activity, as revenue is either nonexistent or minimal. It illustrates the R&D investment phase. Successful commercialization of its immunotherapy will lead to exponential growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BriaCell-Therapeutics-BCTX&v=1772617922756 "Sales chart per company employee BriaCell Therapeutics (BCTX)")
Sales per employee in the market segment - Cancer women
BriaCell Therapeutics (BCTX) is an immuno-oncology company developing personalized breast cancer vaccines. This chart shows the average revenue per employee in the pharmaceutical segment. For BriaCell, which is in the R&D stage, comparing it to this benchmark (zero) highlights their focus on developing complex therapies rather than focusing on current sales.
Sales per employee for the market as a whole
BriaCell Therapeutics (BCTX) is a clinical-stage biotech company focused on breast cancer immunotherapy. It has no revenue. This metric is irrelevant. The company's entire value lies in the potential of its cell therapy and clinical trial data.
Short shares by company, segment and market as a whole
Shares shorted by company BriaCell Therapeutics (BCTX)
BriaCell Therapeutics is a biotech company developing immunotherapy for breast cancer. This chart shows the odds on the failure of their clinical trials. The bears believe their approach will fail in late-stage trials, a common fate for many oncology startups.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BriaCell-Therapeutics-BCTX&v=1772617922794 "Short Shares Chart for the Company BriaCell Therapeutics (BCTX)")
Shares shorted by market segment - Cancer women
BriaCell (BCTX) is a biotech developing a personalized immunotherapy (vaccine) for breast cancer. This chart shows the pessimism in the sector. The surge in shorts across the industry is a bet that this technology will fail. Investors are skeptical of the idea of a "cancer vaccine" and expect BCTX, like many before it, to fail clinical trials.
Shares shorted by the overall market
BriaCell is a biotech company working on breast cancer immunotherapy. This is a niche and risky R&D area. This chart illustrates the overall market pessimism. When investors panic, they're unwilling to fund "long-term science." They see a company burning through cash and sell off shares, fearing they'll run out of money before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BriaCell Therapeutics (BCTX)
This chart demonstrates BriaCell's high sensitivity to clinical data. The company is developing an immunotherapy for the treatment of advanced breast cancer. This is a binary betting market. The publication of encouraging efficacy data, even in a small group of patients, triggers euphoria and "overheating" (above 70). Any doubts about the results or delays lead to panic (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BriaCell-Therapeutics-BCTX&v=1772617922820 "RSI 14 indicator chart for the company's stock BriaCell Therapeutics (BCTX)")
RSI 14 Market Segment - Cancer women
BriaCell is a biotech company focused on women's cancer. They're developing immunotherapy (a cellular vaccine) to treat breast cancer. The "Cancer Women" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether BCTX's growth is due to their R&D, or is the entire biotech sector overheated?
RSI 14 for the overall market
BriaCell (BCTX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BCTX (BriaCell Therapeutics)
BriaCell (BCTX) is an immuno-oncology company developing a cell therapy (Bria-IMT) for the treatment of metastatic breast cancer. This chart shows the average price target, reflecting analysts' belief in this technology and its potential to treat difficult-to-treat forms of cancer.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BCTX-BriaCell-Therapeutics&v=1772617922832 "A chart showing analyst consensus forecasts for the expected stock price. BCTX (BriaCell Therapeutics)")
The difference between the consensus estimate and the actual stock price BCTX (BriaCell Therapeutics)
BriaCell is an immuno-oncology company developing a "vaccine" (Bria-IMT) for the treatment of metastatic breast cancer. This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in this R&D program and its chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BCTX-BriaCell-Therapeutics&v=1772617922842 "A chart showing the difference between the consensus forecast and the actual stock price. BCTX (BriaCell Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer women
BriaCell Therapeutics is a biotech company developing personalized immunotherapy (vaccine) to combat advanced breast cancer. This chart reflects analyst expectations across the oncology sector, demonstrating whether experts believe a breakthrough in breast cancer treatment is possible.
Analysts' consensus forecast for the overall market share price
BriaCell Therapeutics is a biotech company developing immunotherapy (vaccine) for the treatment of breast cancer. This chart shows the overall market "risk appetite." For BriaCell, a high-risk clinical-stage company, overall market optimism (the rising chart) is critical to attracting the capital needed to fund long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BriaCell Therapeutics
BriaCell is a biotech company focused on cancer vaccines. Their R&D platform (Bria-IMT) is a personalized cell therapy designed to train the immune system to attack metastatic breast cancer. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative estimate of their clinical data and their chances of approval.
AKIMA Market Segment Index - Cancer women
BriaCell Therapeutics (BCTX) is an immuno-oncology company developing personalized vaccines for the treatment of breast cancer. Their approach involves training the patient's immune system to attack the tumor. The chart shows the segment average, helping investors assess how BriaCell's risks in this complex field compare to the average.
The AKIM Index for the overall market
BriaCell Therapeutics is an immuno-oncology company developing personalized cell-based vaccines for the treatment of breast cancer. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding this innovative therapy.
